Thiol/Disulfide Balance in Older Patients with BCR-ABL Negative Myeloproliferative Neoplasms

被引:3
|
作者
Koyuncu, Mahmut B. [1 ]
Cavusoglu, Cagatay [2 ]
Basir, Hakan [3 ]
Ilgan, Mustafa [3 ]
Ucar, Mehmet A. [1 ]
Akdeniz, Aydan [1 ]
Tombak, Anil [1 ]
Tiftik, Eyup N. [1 ]
Temel, Gulhan O. [4 ]
Neselioglu, Salim [5 ]
Erel, Ozcan [5 ]
机构
[1] Mersin Univ, Fac Med, Dept Hematol, Mersin, Turkey
[2] Hacettepe Univ, Fac Med, Dept Geriatr, Ankara, Turkey
[3] Mersin Univ, Fac Med, Dept Internal Med, Mersin, Turkey
[4] Mersin Univ, Fac Med, Dept Biostat, Mersin, Turkey
[5] Yildirim Beyazit Univ, Fac Med, Dept Med Biochem, Ankara, Turkey
关键词
oxidative stress; older adults; myeloproliferative neoplasms; ISCHEMIA-MODIFIED ALBUMIN; OXIDATIVE STRESS; POLYCYTHEMIA-VERA; ASXL1; MUTATIONS; CALRETICULIN; HOMEOSTASIS; MAINTENANCE; BIOMARKER; CELLS; ASSAY;
D O I
10.7754/Clin.Lab.2021.210324
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The trio Essential Thrombocytosis (ET), Polycythemia Vera (PV), and Primary Myelofibrosis (PM) are BCR-ABL negative myeloproliferative neoplasms. All three diseases have the risk of transforming into acute leukemia. Oxidative stress and some genetic mutations increase the risk of leukemic transformation. The median age in patients with ET, PV, and MF is around 64 years, and it is expected to exceed 65 in the coming years. Since oxidative stress increases with age, we aimed to evaluate the oxidative stress parameters in older patients with myeloproliferative neoplasms. Methods: The study included a total of 160 patients (57 patients with Essential Thrombocytosis, 52 patients with Primary Myelofibrosis, and 51 patients with Polycythemia Vera) and 56 healthy controls, aged 65 and over. Ischemia Modified Albumin (IMA) and thiol parameters (native thiol, total thiol, and disulfide) were studied from serum samples taken at the time of diagnosis. Results: The median age of the patients was 69 (65 - 85) years. Patients had higher levels of IMA and lower levels of thiol compared to the control group (p < 0.001). When evaluated according to disease subgroups, it was observed that the highest IMA levels and the lowest thiol levels were in patients with PM (p < 0.001). Higher IMA levels and lower native thiol levels were found in patients with the ASXL1 mutation (p < 0.001). Conclusions: Serum IMA and thiol levels are also significantly changed in older patients with BCR-ABL negative myeloproliferative neoplasia. Changes in these markers are independent of age. Disease-associated mutations such as ASXL1 can also affect the serum levels of these markers.
引用
收藏
页码:2700 / 2706
页数:7
相关论文
共 50 条
  • [1] BCR-ABL negative myeloproliferative neoplasms
    Metzgeroth, G.
    Lengfelder, E.
    Griesshammer, M.
    Reiter, A.
    ONKOLOGE, 2012, 18 (12): : 1130 - +
  • [2] Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with BCR-ABL negative myeloproliferative neoplasms
    Davidson, Marta
    Wong, Florence
    Atri, Mostafa
    Sibai, Hassan
    Maze, Dawn
    Cheung, Verna
    Callum, Jeannie
    Atenafu, Eshetu G.
    Gupta, Vikas
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : E88 - E90
  • [3] Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL -Negative Myeloproliferative Neoplasms
    Wille, Kai
    Deventer, Eva
    Sadjadian, Parvis
    Becker, Tatjana
    Kolatzki, Vera
    Huenerbein, Karlo
    Meixner, Raphael
    Jimenez-Munoz, Marina
    Fuchs, Christiane
    Griesshammer, Martin
    HAMOSTASEOLOGIE, 2024, 44 (05): : 386 - 392
  • [4] High rate of secondary primary malignancies in patients with BCR-ABL negative myeloproliferative neoplasms
    Wille, K.
    Sadjadian, P.
    Becker, T.
    Horstmann, A.
    Kolatzki, V
    Griesshammer, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 28 - 28
  • [5] Therapeutic potential of Axl blockade in BCR-ABL negative myeloproliferative neoplasms (MPN)
    Beitzen-Heineke, A.
    Ben Batalla, I
    Paesler, S.
    Gensch, V
    Schafhausen, P.
    von Amsberg, G.
    Riecken, K.
    Fischer, T.
    Pantel, K.
    Bokemeyer, C.
    Loges, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 27 - 27
  • [6] Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)
    Beitzen-Heineke, Antonia
    Ben Batalla, Isabel
    Berenbrok, Nikolaus
    Paesler, Sarina
    Gensch, Victoria
    von Amsberg, Gunhild
    Schafhausen, Philippe
    Riecken, Kristoffer
    Fischer, Thomas
    Pantel, Klaus
    Bokemeyer, Carsten
    Loges, Sonja
    BLOOD, 2018, 132
  • [7] BCR-ABL-negative myeloproliferative NeoplasienBCR-ABL negative myeloproliferative neoplasms
    G. Metzgeroth
    E. Lengfelder
    M. Griesshammer
    A. Reiter
    Der Onkologe, 2012, 18 (12): : 1130 - 1138
  • [8] Evaluation of hMICL As a Marker Associated with Disease Progression in BCR-ABL Negative Myeloproliferative Neoplasms
    Nederby, Line
    Larsen, Laura Laine
    Hokland, Peter
    Roug, Anne Stidsholt
    BLOOD, 2012, 120 (21)
  • [9] The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
    Strickland, Marie
    Quek, Lynn
    Psaila, Bethan
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (05) : 1149 - 1158
  • [10] AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
    Beitzen-Heineke, Antonia
    Berenbrok, Nikolaus
    Waizenegger, Jonas
    Paesler, Sarina
    Gensch, Victoria
    Udonta, Florian
    Delgado, Maria Elena Vargas
    Engelmann, Janik
    Hoffmann, Friederike
    Schafhausen, Philippe
    von Amsberg, Gunhild
    Riecken, Kristoffer
    Beumer, Niklas
    Imbusch, Charles D.
    Lorens, James
    Fischer, Thomas
    Pantel, Klaus
    Bokemeyer, Carsten
    Ben-Batalla, Isabel
    Loges, Sonja
    HEMASPHERE, 2021, 5 (09): : E630